Second Genome Overview
- Founded
-
2009
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
2ndary - Private
- Investors
-
16
Second Genome General Information
Description
Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision therapies and biomarkers. The company's platform uses a microbiome data platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites from the microbiome, enabling researchers to develop medicines through microbiome science.
Contact Information
Website
www.secondgenome.com
Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1000 Marina Boulevard
- Suite 500
- Brisbane, CA 94005
- United States
+1 (650) 000-0000
Second Genome Timeline
Second Genome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 01-Sep-2021 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 6. Later Stage VC (Series B) | 15-Mar-2019 | 0000 | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 01-Jan-2019 | 00.000 | 000.00 | Completed | Startup | |
| 4. Later Stage VC (Series B) | 14-May-2017 | 000.00 | 000.00 | 0000 | Completed | Startup |
| 3. Early Stage VC (Series A) | 07-Jun-2013 | 00.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 09-Aug-2011 | $5M | $6.24M | 000.00 | Completed | Startup |
| 1. Seed Round | 07-Jul-2010 | $1.24M | $1.24M | 00.00 | Completed | Startup |
Second Genome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 5,607,290 | $0.000100 | $0.02 | $0.22 | $0.22 | 1x | $0.22 | 1.45% |
Second Genome Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision t
Drug Discovery
Brisbane, CA
13
As of 2023
000.00
00000000000
000.00
000000
mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
San Diego, CA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
000000
ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Emeryville, CA
000
As of 0000
00000
00000000000
00000
Add Comparison
Second Genome Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Locanabio | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 000000 | Formerly VC-backed | Emeryville, CA | 000 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | Vancouver, Canada | 000 | 00000 | 00000000 | 00000 |
| 00000 (0000 000000 | Formerly VC-backed | Somerville, MA | 000 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Dublin, OH | 0 | 000.00 | 0000 | 000.00 |
Second Genome Patents
Second Genome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3905893-A1 | Microbially derived peptides and proteins for immunotherapy | Pending | 06-Jan-2019 | 0000000000 | |
| EP-3905893-A4 | Microbially derived peptides and proteins for immunotherapy | Pending | 06-Jan-2019 | 0000000000 | |
| US-20220089653-A1 | Microbially derived peptides and proteins for immunotherapy | Pending | 06-Jan-2019 | 0000000000 | |
| EP-3863655-A1 | Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders | Pending | 09-Oct-2018 | 0000000000 | |
| EP-3863655-A4 | Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders | Pending | 09-Oct-2018 | C12N15/746 |
Second Genome Executive Team (19)
Second Genome Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barbara Dalton Ph.D | Pfizer Ventures | Board Member | 000 0000 |
| Bradley Margus | Self | Board Member | 000 0000 |
| Carole Nuechterlein JD | Roche Venture Fund | Board Member | 000 0000 |
| Corey Goodman Ph.D | Self | Co-Founder and Chairman | 000 0000 |
| Elaine Jones Ph.D | Pfizer Ventures | Board Member | 000 0000 |
Second Genome Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Second Genome Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| MBL Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Digitalis Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Justin Kuczynski | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Lifeforce Capital | Venture Capital | Minority | 000 0000 | 000000 0 |